Genetic Technologies Limited DU8S.F Stock
Genetic Technologies Limited Price Chart
Genetic Technologies Limited DU8S.F Financial and Trading Overview
Genetic Technologies Limited stock price | 0.49 EUR |
Previous Close | 0.9 EUR |
Open | 0.89 EUR |
Bid | 0.88 EUR x N/A |
Ask | 0.92 EUR x N/A |
Day's Range | 0.89 - 0.89 EUR |
52 Week Range | 0.77 - 3 EUR |
Volume | 111 EUR |
Avg. Volume | 1 EUR |
Market Cap | 21.48M EUR |
Beta (5Y Monthly) | 0.560153 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
DU8S.F Valuation Measures
Enterprise Value | 9.42M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.999911 |
Price/Book (mrq) | 1.4833332 |
Enterprise Value/Revenue | 0.877 |
Enterprise Value/EBITDA | -1.089 |
Trading Information
Genetic Technologies Limited Stock Price History
Beta (5Y Monthly) | 0.560153 |
52-Week Change | -13.46% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3 EUR |
52 Week Low | 0.77 EUR |
50-Day Moving Average | 0.9 EUR |
200-Day Moving Average | 1.07 EUR |
DU8S.F Share Statistics
Avg. Volume (3 month) | 1 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 19.24M |
Float | 13.09M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 6.55% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | -81.088% |
Operating Margin (ttm) | -84.19% |
Gross Margin | 62.45% |
EBITDA Margin | -80.53% |
Management Effectiveness
Return on Assets (ttm) | -29.56% |
Return on Equity (ttm) | -57.15% |
Income Statement
Revenue (ttm) | 10.74M EUR |
Revenue Per Share (ttm) | 0.6 EUR |
Quarterly Revenue Growth (yoy) | 44.10% |
Gross Profit (ttm) | 6.2M EUR |
EBITDA | -8650729 EUR |
Net Income Avi to Common (ttm) | -8709925 EUR |
Diluted EPS (ttm) | -0.34 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 5.05M EUR |
Total Cash Per Share (mrq) | 0.33 EUR |
Total Debt (mrq) | 612.39K EUR |
Total Debt/Equity (mrq) | 5.55 EUR |
Current Ratio (mrq) | 2.08 |
Book Value Per Share (mrq) | 0.6 |
Cash Flow Statement
Operating Cash Flow (ttm) | -7654500 EUR |
Levered Free Cash Flow (ttm) | -3807009 EUR |
Profile of Genetic Technologies Limited
Country | Germany |
State | VIC |
City | Fitzroy |
Address | 60-66 Hanover Street |
ZIP | 3065 |
Phone | 61 3 8412 7000 |
Website | https://genetype.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 52 |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Q&A For Genetic Technologies Limited Stock
What is a current DU8S.F stock price?
Genetic Technologies Limited DU8S.F stock price today per share is 0.49 EUR.
How to purchase Genetic Technologies Limited stock?
You can buy DU8S.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genetic Technologies Limited?
The stock symbol or ticker of Genetic Technologies Limited is DU8S.F.
Which industry does the Genetic Technologies Limited company belong to?
The Genetic Technologies Limited industry is Diagnostics & Research.
How many shares does Genetic Technologies Limited have in circulation?
The max supply of Genetic Technologies Limited shares is 5.75M.
What is Genetic Technologies Limited Price to Earnings Ratio (PE Ratio)?
Genetic Technologies Limited PE Ratio is 0.00000000 now.
What was Genetic Technologies Limited earnings per share over the trailing 12 months (TTM)?
Genetic Technologies Limited EPS is 0 EUR over the trailing 12 months.
Which sector does the Genetic Technologies Limited company belong to?
The Genetic Technologies Limited sector is Healthcare.